• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Aravive Inc.

    1/29/24 4:16:18 PM ET
    $ARAV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARAV alert in real time by email
    S-8 POS 1 arav20240128d_s8pos.htm FORM S-8 POS arav20240128d_s8pos.htm

    As filed with the Securities and Exchange Commission on January 29, 2024

    Registration No. 333-271335

    333-264445

    333-254400

    333-237425

    333-233866

    333-230348

    333-227865

    333-216586

    333-210013

    333-204178

    333-194949

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    Post-Effective Amendment No. 1 to Registration Statement No. 333-271335

     

    Post-Effective Amendment No. 1 to Registration Statement No. 333-264445

     

    Post-Effective Amendment No. 1 to Registration Statement No. 333-254400

     

    Post-Effective Amendment No. 1 to Registration Statement No. 333-237425

     

    Post-Effective Amendment No. 1 to Registration Statement No. 333-233866

     

    Post-Effective Amendment No. 1 to Registration Statement No. 333-230348

     

    Post-Effective Amendment No. 1 to Registration Statement No. 333-227865

     

    Post-Effective Amendment No. 1 to Registration Statement No. 333-216586

     

    Post-Effective Amendment No. 1 to Registration Statement No. 333-210013

     

    Post-Effective Amendment No. 1 to Registration Statement No. 333-204178

     

    Post-Effective Amendment No. 1 to Registration Statement No. 333-194949

     

    UNDER THE SECURITIES ACT OF 1933

     

    ARAVIVE, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    26-4106690

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification Number)

     

    River Oaks Tower

    3730 Kirby Drive, Suite 1200

    Houston, Texas 77098

    (Address, including zip code, of principal executive offices)

     

     

     

     

    Aravive, Inc. 2019 Equity Incentive Plan

    Aravive, Inc. 2014 Equity Incentive Plan

    Aravive, Inc. 2014 Employee Stock Purchase Plan

    Versartis, Inc. 2014 Equity Incentive Plan

    Versartis, Inc. 2014 Employee Stock Purchase Plan

    Versartis, Inc. 2009 Stock Plan

    (Full title of the plans)

     

    Gail McIntyre

    Secretary and Authorized Officer

    River Oaks Tower

    3730 Kirby Drive, Suite 1200

    Houston, Texas 77098

    (936) 355-1910

    (Name, address of and telephone number, including area code, of agent for service)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

       

    Emerging growth company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act ☐

     

     

     

     

    EXPLANATORY NOTE

     

    On January 17, 2024, Aravive, Inc. (the “Company”) announced its intention to voluntarily terminate the listing of its shares of common stock, par value $0.0001 per share (the “Common Stock”) from the Nasdaq Global Select Market (the “Delisting”). On October 2, 2023, at the Company’s 2023 Annual Meeting of Stockholders, the Company’s stockholders approved the transfer of all or substantially all of the Company's assets through an assignment for the benefit of creditors (the “Assignment”) if the Company’s Board of Directors (the “Board”) deemed such transfer to be in the best interests of the Company, which Assignment the Board approved on January 12, 2024. The Company subsequently filed a Form 25 with the Securities and Exchange Commission (the “SEC”) in connection with the Delisting. In connection with the foregoing and the undertakings in the Registration Statements (as defined below), the Company is hereby filing this Post-Effective Amendment to each of the Company’s registration statements on Form S-8 (Registration Nos. 333-271335, 333-264445, 333-254400, 333-237425, 333-233866, 333-230348, 333-227865, 333-216586, 333-210013, 333-204178 and 333-194949) (collectively, the “Registration Statements”) to terminate the effectiveness of each such Registration Statement and to remove from registration all of the Company’s securities that remain unsold under each such Registration Statement.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Houston, State of Texas, on or before January 29, 2024.

     

      ARAVIVE, INC.  
         
         
      By:  /s/ Gail McIntyre  
      Gail McIntyre  
      Secretary and  
      Authorized Officer  

     

    Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign this Post-Effective Amendment to the Registration Statements.

     

     

     
    Get the next $ARAV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARAV

    DatePrice TargetRatingAnalyst
    4/17/2023$12.00Buy
    BTIG Research
    6/3/2022$15.00Buy
    ROTH Capital
    More analyst ratings

    $ARAV
    SEC Filings

    See more
    • SEC Form 15-12G filed by Aravive Inc.

      15-12G - Aravive, Inc. (0001513818) (Filer)

      2/8/24 7:00:50 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Aravive Inc.

      EFFECT - Aravive, Inc. (0001513818) (Filer)

      2/2/24 12:15:24 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Aravive Inc.

      EFFECT - Aravive, Inc. (0001513818) (Filer)

      2/2/24 12:15:15 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Petrini Maria Carolina

      4 - Aravive, Inc. (0001513818) (Issuer)

      4/11/23 4:07:42 PM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Petrini Maria Carolina

      3 - Aravive, Inc. (0001513818) (Issuer)

      4/11/23 4:07:00 PM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Mcintyre Gail Frances

      4 - Aravive, Inc. (0001513818) (Issuer)

      2/2/23 4:25:16 PM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research resumed coverage on Aravive with a new price target

      BTIG Research resumed coverage of Aravive with a rating of Buy and set a new price target of $12.00

      4/17/23 9:01:46 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH Capital initiated coverage on Aravive with a new price target

      ROTH Capital initiated coverage of Aravive with a rating of Buy and set a new price target of $15.00

      6/3/22 9:00:32 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Aravive with a new price target

      BTIG Research initiated coverage of Aravive with a rating of Buy and set a new price target of $26.00

      3/15/21 8:09:54 AM ET
      $ARAV
      Biotechnology: Pharmaceutical Preparations
      Health Care